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Molecularly defined subgroups of tumors characterized by specific driver mutations have been identified in the
majority of cancers. The availability of novel drugs capable of targeting signaling pathways activated by genetic
derangements has led to hypothesize the possibility to treat patients based on their genomic profile. A clear
example is represented by lung adenocarcinoma for which it has been possible to identify driver genetic alterations
in approximately 75% of the cases. Among these, RET fusion transcripts are detectable in about 1–2% of lung
adenocarcinomas and might represent targets for therapeutic intervention with RET kinase inhibitors. However, a
number of issues need to be addressed to make genomics-driven oncology routinely accessible for cancer patients,
including: 1) the availability of novel methods in molecular diagnostics that allow a comprehensive molecular
characterization of lung tumors starting from a low input DNA/RNA; 2) identification of reliable and reproducible
biomarkers of response/resistance to targeted agents; 3) the assessment of the role of tumor heterogeneity in the
response to drugs targeting molecular pathways.
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Somatic alterations of genes involved in the regulation
of cell proliferation, differentiation and survival play a
pivotal role in the pathogenesis and progression of the
majority of human cancers. In many cancer types it has
been possible to identify molecularly defined subgroups
of tumors that are characterized by driver mutations
(genetic alterations causally associated with carcinogen-
esis) that are often mutually exclusive [1]. An example is
represented by the adenocarcinoma subgroup of non-
small-cell lung cancer (NSCLC), in which using high
throughput technology it has been possible to identify
driver genetic alterations in approximately 75% of the
cases [2].
The identification of such driver mutations and the
availability of novel drugs capable of targeting signaling
pathways activated by genetic derangements has led to
hypothesize the possibility to treat patients based on
their genomic profile (Table 1). An example of this* Correspondence: nicnorm@yahoo.com
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article, unless otherwise stated.potential approach, defined genomics driven-oncology, is
represented by RET rearrangements in lung cancer [3].
Chimeric RET proteins generated by chromosomal rear-
rangements leading to RET fusion transcripts have been
identified in ~1–2% of lung adenocarcinomas but might
represent as many as 6–19% of tumors from never-
smokers without other driver mutations [3]. Response to
treatment with RET inhibitors such as vandetanib or
cabozantinib has been reported in selected cases [4-7].
Phase 2 clinical trials of RET kinase inhibitors in lung
cancer patients harboring RET rearrangement are on-
going (Table 2). In this regard, a retrospective analysis of
RET translocations, gene copy number gains and expres-
sion from four randomized trials of vandetanib in NSCLC
is published in this issue of BMC Cancer [8]. Noteworthy,
this is the first series of patients from clinical trials that
have been extensively screened for RET molecular alter-
ations, although retrospectively.
Discussion
While the absolute number of RET-positive tumors
reported in the paper by Platt et al. [8] is too low to
draw any firm conclusion, this study provides importantCentral. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
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Table 1 Selected genetic alterations representing
potential biomarkers in lung adenocarcinoma and
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the entire field of genomics-driven oncology:
1. The rate of RET rearrangement in NSCLC was as
low as 0.7%, while previous studies have reported
frequencies up to 6%. RET rearrangements have
been suggested to be more frequent in Asian
patients, in non-smoker and in the adenocarcinoma
subgroup. Therefore, the selection of the study
population might significantly affect the frequency at
which RET rearrangements are detected. In addition,
RET rearrangement is usually mutually exclusive to
other driver mutations, and its frequency results
higher in patients that do not harbor the more
frequent KRAS and EGFR mutations [3].
Nevertheless, this observation poses a major
problem for molecular diagnostics that is common
to many cancer types. In fact, the number of poten-
tial predictive biomarkers that might offer possibility
of therapeutic intervention in lung cancer as well as
in other tumor types is increasing exponentially
(Table 1). Identification of driver mutations might
result in a survival advantage for cancer patients that
have access to novel drugs through clinical trials or,
in selected cases, to receive an off-label treatment
with agents approved for other indications [9].
However, the time, the cost, and the amount ofTable 2 Phase II clinical trials of RET tyrosine kinase inhibitors
Study identifier Drug (dose) Molecular tar
NCT01639508 cabozantinib (60 mg/day) MET, VEGFR2,
NCT01823068 vandetanib (300 mg/day) VEGFR2, EGFR,
NCT01813734 ponatinib (45 mg/day) ABL, FLT3, KIT,
*objective response rate.tissue needed for a wide molecular profiling using
routine diagnostic methods are not compatible with
the standard clinical workup, in particular in lung
cancer. In many European countries diagnosis of
lung cancer is based in over 50% of the cases on
cytology samples or small biopsies that might not be
sufficient for analysis of somatic mutations and gene
rearrangements in several different genes using
sequencing, Real Time PCR and/or FISH. Indeed, a
26.9% failure rate in FISH analysis due to an
inadequate number of tumor cells or sample quality
was reported by Platt and colleagues [8]. This
observation underlines the need for novel methods
in molecular diagnostics that allow a comprehensive
molecular characterization of lung tumors in the
routine clinical workout [10]. In this respect,
different methods to detect mutations and fusions
using genotyping or targeted next generation
sequencing are being explored, and might be
ready in a short timeframe for clinical
implementation [11-14].
2. Oncogenic pathways can be activated by different
molecular mechanisms. Indeed, Platt and colleagues
found RET amplification in 2.8% of the cases, low
RET gene copy number gain in 8.1%, and RET
protein expression in 8.3% [8]. Although the relative
low number of positive cases prevents any firm
conclusion, the finding that the response rate to
vandetanib did not correlate with any of these
markers does suggest that they have little predictive
utility to identify those patients who will benefit
from vandetanib therapy. This observation has two
important implications. First, activation of RET
through amplification or low copy number gain
might not represent a driver molecular alteration in
lung cancer. In addition, based on the data
presented in this issue of BMC Cancer by Platt et al.
[8], immunohistochemical detection of RET protein
is not a surrogate of RET rearrangement. In fact,
RET protein expression was found in cases that did
not harbor RET rearrangement. Surprisingly, no
RET protein expression was found in some cases
with RET rearrangement. This might be due to
technical limitations of the immunohistochemistry
protocol. Nevertheless, it might be worth to explore
whether protein expression levels might affectin RET-rearranged lung carcinoma
gets Primary outcome measure
FLT3, c-KIT, AXL and RET ORR*
RET and FGFR-1 ORR
FGFR, PDGFR, VEGFR2 and RET ORR
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rearranged lung tumors.
3. Only three RET-rearrangement positive patients
received vandetanib treatment in the trials reported
by Platt et al. [8], and this low number does not
allow to make any conclusion regarding association
of vandetanib treatment with efficacy in the RET
rearrangement positive subpopulation. However,
it is quite surprising that none of the three
vandetanib-treated RET-rearrangement-positive
patients had an objective response. Importantly, one
patient received a 100 mg dose of vandetanib in the
ZODIAC trial. Two patients were treated with the
standard 300 mg dose of vandetanib in the ZEPHYR
study, and both showed radiologic evidence of
tumor shrinkage although a response could not be
confirmed at the next visit. The ongoing phase 2
clinical trial of vandetanib in lung cancer patients
harboring RET rearrangement is employing a
300 mg dose and will clear out the efficacy of the
drug in this subgroup of patients (Table 2).
Nevertheless, we have come to expect that a tumor
harboring a driver mutation will respond to a
specific inhibitor, which was not the case in this
study. On the other hand, increasing evidence
suggests that tumors, including lung carcinoma, are
heterogeneous: many tumors contain several clones
of neoplastic cells that accumulate during tumor
progression different molecular alterations, which
might represent mechanisms of resistance to
target-based agents [15]. Therefore, it is possible
that even tumors with a driver mutation show
resistance to specific inhibitors. Indeed, the
response rate of lung cancer patients with EGFR
mutations to EGFR tyrosine kinase inhibitors ranged
between 56% and 86% in different clinical trials, thus
suggesting that primary resistance is a phenomenon
common to different tumors with driver mutations
[16]. In this regard, a more comprehensive
molecular characterization of lung tumors might
allow to better identify those patients that will
benefit from specific targeted agents.
Conclusion
Identification of relatively rare mutations is transforming
tumors with high incidence such as lung adenocar-
cinoma in some rare diseases, each characterized by a
specific molecular alteration. Molecular classification of
lung tumors based on driver mutations represents a
major challenge for molecular diagnostics, but also an
important opportunity for cancer patients to access to
novel drugs. In this regard, a number of issues need still
to be addressed to make genomics-driven oncology rou-
tinely accessible for cancer patients.Competing interests
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